{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:18:53Z","timestamp":1794712733306,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pluri Biotech, Ltd."},{"name":"Pluri-Biotch Ltd."},{"name":"Pluri-Biotech, Ltd."},{"name":"Pluri Biotech Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Persistent cytopenia in the post-hematopoietic cell transplantation (HCT) setting can occur despite adequate engraftment of donor cells. PLX-R18, a placental-derived mesenchymal-like cell product, is expanded ex vivo in a 3-dimensional environment. PLX-R18 cells secrete a large array of hematopoietic factors, which promote regeneration, maturation, and differentiation of hematopoietic cells and stimulate their migration to peripheral blood. This phase 1, first-in-human study (NCT03002519), included 21 patients with incomplete hematopoietic recovery post-HCT. Patients were treated with escalating doses of PLX-R18: 3 patients received 1 million cells\/kg, 6 received 2 million cells\/kg, and 12 received 4 million cells\/kg via multiple intramuscular injections. While patients received only two administrations of cells during the first week, peripheral blood counts continued to increase for months, peaking at 6 months for hemoglobin (Hb, <jats:italic>p<\/jats:italic>\u2009=\u20090.002), lymphocytes (<jats:italic>p<\/jats:italic>\u2009=\u20090.008), and neutrophils (ANC, <jats:italic>p<\/jats:italic>\u2009=\u20090.063), and at 9 months for platelets (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and was maintained until 12 months for all but ANC. The need for platelet transfusions was reduced from 5.09 units\/month at baseline to 0.55 at month 12 (<jats:italic>p<\/jats:italic>\u2009=\u20090.05). Likewise, red blood cell transfusions decreased from 2.91 units\/month at baseline to 0 at month 12 (<jats:italic>p<\/jats:italic>\u2009=\u20090.0005). PLX-R18 was safe and well tolerated and shows promise in improving incomplete hematopoietic recovery post-HCT.<\/jats:p>","DOI":"10.1038\/s41409-023-02068-3","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T10:01:48Z","timestamp":1691488908000},"page":"1189-1196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study"],"prefix":"10.1038","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph P.","family":"McGuirk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1980-9999","authenticated-orcid":false,"suffix":"III","given":"Leland","family":"Metheny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Pineiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3299-835X","authenticated-orcid":false,"given":"Scott D.","family":"Rowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batia","family":"Avni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2386-0850","authenticated-orcid":false,"given":"Roni","family":"Tamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-5607","authenticated-orcid":false,"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Sheleg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rothenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitsan","family":"Halevy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6204-977X","authenticated-orcid":false,"given":"Tsila","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"key":"2068_CR1","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","volume":"27","author":"MA Kharfan","year":"2021","unstructured":"Kharfan MA, Kumar A, Ayala E, Aljurt M, Nishihori T, Marsh R, et al. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transpl Cell Ther. 2021;27:642\u20139.","journal-title":"Transpl Cell Ther"},{"key":"2068_CR2","doi-asserted-by":"publisher","first-page":"911174","DOI":"10.3389\/fimmu.2022.911174","volume":"13","author":"Y Man","year":"2022","unstructured":"Man Y, Lu Z, Yao X, Gong Y, Yang T, Wang Y. Recent advancements in poor graft function following hematopoietic stem cell transplantation. Front Immunol. 2022;13:911174.","journal-title":"Front Immunol"},{"key":"2068_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.transci.2018.04.014","volume":"57","author":"ZN Ozdemir","year":"2018","unstructured":"Ozdemir ZN, Bozdag SC. Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation. Transfusion Apheresis Sci. 2018;57:163\u20137.","journal-title":"Transfusion Apheresis Sci"},{"key":"2068_CR4","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.bbmt.2019.05.036","volume":"25","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Gao F, Shi J, Luo Y, Tan Y, Lai X, et al. Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019;25:1898\u2013907.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2068_CR5","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/bmt.2016.98","volume":"51","author":"H Alchalby","year":"2016","unstructured":"Alchalby H, Yunus D-R, Zabelina T, Ayuk F, Kroger N. Incidence and Risk Factors of Poor Graft Function After Allogeneic Stem Cell Transplantation for Myelofibrosis. Bone Marrow Transplant. 2016;51:1223\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"2068_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1046\/j.1365-2141.2001.02468.x","volume":"112","author":"A Dominietto","year":"2001","unstructured":"Dominietto A, Raiola AM, Van Lint MT, Lamparelli T, Gualandi F, Berisso G, et al. Factors Influencing Haematological Recovery after Allogeneic Haemopoietic Stem Cell Transplants: Graft-Versus-Host Disease, Donor Type, Cytomegalovirus Infections and Cell Dose. Br J Haematol. 2001;112:219\u201327.","journal-title":"Br J Haematol"},{"key":"2068_CR7","first-page":"4529","volume":"130","author":"F Lutfi","year":"2017","unstructured":"Lutfi F, Skelton PW, Rosenau E, Farhadfar N, Murthy HS, May S, et al. Poor Graft Function Following Autologous Stem Cell Transplant. Abstract from the 2017 American Society of Hematology Meeting. Blood. 2017;130:4529.","journal-title":"Blood."},{"key":"2068_CR8","doi-asserted-by":"publisher","first-page":"877.e1","DOI":"10.1016\/j.jtct.2021.07.012","volume":"27","author":"M Shahzad","year":"2021","unstructured":"Shahzad M, Siddiqui RS, Anwar I, Chaudhary SG, Ali T, Naseem M, et al. Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Transpl Cell Ther. 2021;27:877.e1\u2013877.e8.","journal-title":"Transpl Cell Ther"},{"key":"2068_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12185-021-03153-3","volume":"114","author":"S Giammarco","year":"2021","unstructured":"Giammarco S, Sica S, Chiusolo P, Laurenti L, Sora F, Martino M, et al. Eltrombopag for the Treatment of Poor Graft Function Following Allogeneic Stem Cell Transplant: A Retrospective Multicenter Study. Int J Hematol. 2021;114:228\u201334.","journal-title":"Int J Hematol"},{"key":"2068_CR10","doi-asserted-by":"crossref","unstructured":"Lazarus HM, Gerson SL. The History of Stem Cell Transplantation. In: Vertes AA, Qureshi N, Caplan AIBabiss LE (eds). Stem Cells in Regenerative Medicine: Science, regulation and Business Strategies. 1st ed. John Wiley & Sons, 2015. pp 69\u201385.","DOI":"10.1002\/9781118846193.ch5"},{"key":"2068_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jocit.2014.12.001","volume":"2","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Ren H, Han Z. Mesenchymal Stem Cells: Immunomodulatory Capability and Clinical Potential in Immune Diseases. J Cell Immunother. 2016;2:3\u201320.","journal-title":"J Cell Immunother"},{"key":"2068_CR12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/sj.leu.2404550","volume":"3","author":"L Fouillard","year":"2007","unstructured":"Fouillard L, Chapel A, Bories D, Bouchet S, Costa J-M, Rouard H, et al. Infusion of Allogeneic-related HLA Mismatched Mesenchymal Stem Cells for the Treatment of Incomplete Engraftment Following Autologous Haematopoietic Stem Cell Transplantation. Leukemia. 2007;3:568\u201370.","journal-title":"Leukemia."},{"key":"2068_CR13","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1089\/scd.2009.0029","volume":"18","author":"N Meuleman","year":"2009","unstructured":"Meuleman N, Tondreau T, Ahmad I, Kwan J, Crokaert F, Delforge A, et al. Infusion of Mesenchymal Stromal Cells Can Aid Hematopoietic Recovery Following Allogeneic Hematopoietic Stem Cell Myeloablative Transplant: A Pilot Study. Stem Cell Development. 2009;18:1247\u201352.","journal-title":"Stem Cell Development."},{"key":"2068_CR14","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/j.1537-2995.2011.03400.x","volume":"52","author":"FM S\u00e1nchez-Guijo","year":"2012","unstructured":"S\u00e1nchez-Guijo FM, L\u00f3pez-Villar O, L\u00f3pez-Anglada L, Villar\u00f3n EM, Munti\u00f3n S, D\u00edez-Campelo M, et al. Allogeneic Mesenchymal Stem Cell Therapy for Refractory Cytopenias After Hematopoietic Stem Cell Transplantation. Transfusion. 2012;52:1086\u201391.","journal-title":"Transfusion."},{"key":"2068_CR15","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.3727\/096368912X661319","volume":"23","author":"X Liu","year":"2014","unstructured":"Liu X, Wu M, Peng Y, Chen X, Sun J, Huang F, et al. Improvement in Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation Upon Administration of Mesenchymal Stem Cells from Third-Party Donors: A Pilot Prospective Study. Cell Transplant. 2014;23:1087\u201398.","journal-title":"Cell Transplant"},{"key":"2068_CR16","doi-asserted-by":"crossref","unstructured":"Gaberman E, Pinzur L, Levdansky L, Tsirlin M, Netzer N, Aberman Z, et al. Mitigation of Lethal Radiation Syndrome in Mice by Intramuscular Injection of 3D Cultured Adherent Human Placental Cells. PLoS One. 2013;8:e66549.","DOI":"10.1371\/journal.pone.0066549"},{"key":"2068_CR17","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/jcsm.12342","volume":"9","author":"L Pinzur","year":"2018","unstructured":"Pinzur L, Akyuez L, Levdansky L, Blumenfeld M, Volinsky E, Aberman Z, et al. Rescue from Lethal Acute Radiation Syndrome (ARS) with Severe Weight Loss by Secretome of Intramuscularly Injected Human Placental Stromal Cells. J Cachexia Sarcopania Muscle. 2018;9:1079\u201392.","journal-title":"J Cachexia Sarcopania Muscle"},{"key":"2068_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/cells9010127","volume":"9","author":"A Papait","year":"2020","unstructured":"Papait A, Vertua E, Magatti M, Ceccariglia S, De Munari S, Silini AR, et al. Mesenchymal Stromal Cells from Fetal and Maternal Placenta Pissess Key Similarities and Differences: Potential Implications For Their Applications in Regenerative Medicine. Cells. 2020;9:127.","journal-title":"Cells."},{"key":"2068_CR19","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1182\/bloodadvances.2021004537","volume":"6","author":"A Prabahran","year":"2022","unstructured":"Prabahran A, Koldej R, Chee L, Ritchie D. Clinical features, Pathophysiology, and Therapy of Poor Graft Function Post-Allogeneic Stem Cell transplantation. Blood Adv. 2022;6:1947\u201359.","journal-title":"Blood Adv"},{"key":"2068_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2040620720948743","volume":"11","author":"J Chen","year":"2020","unstructured":"Chen J, Wang H, Zhou J, Feng S. Advances in the Understanding of Poor Graft Function Following Allogeneic Hematopoietic Stem-cell Transplantation. Ther Adv Hematol. 2020;11:1\u201313.","journal-title":"Ther Adv Hematol"},{"key":"2068_CR21","unstructured":"Pluri-biotech data on file, PLX-R18 Investigator Brochure, March 17th 2022."},{"key":"2068_CR22","unstructured":"Pluri-Biotech data on file, PLX-R18 CMC V4, section P.8.3.4, In-use stability."},{"key":"2068_CR23","unstructured":"Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User\u2019s Manual. Boston, MA: Health Assessment Lab, 1994."},{"key":"2068_CR24","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00277-015-2440-x","volume":"94","author":"YQ Sun","year":"2015","unstructured":"Sun YQ, He GL, Chang YJ, Xu LP, Zhang XH, Han W, et al. The Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function After Unmanipulated Haploidentical Stem Cell Transplantation. Ann Hematol. 2015;94:1699\u2013705.","journal-title":"Ann Hematol"},{"key":"2068_CR25","unstructured":"Muskens KF, Lindemans CA, Dandis R, Nierkens S, Belderbos ME. Blood Rev. 2023; in press."},{"key":"2068_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.18620\/ctt-1866-8836-2019-8-2-38-44","volume":"8","author":"TA Rudakova","year":"2019","unstructured":"Rudakova TA, Kulagin AD, Moiseev IS, Bykova TA, Bondakenko SN, Barabanshikova MV, et al. Thrombopoietin Receptor Agonists for treatment of Poor graft Function after Allogeneic Hematopoietic Stem Cell Transplantation in Adults. Cell Ther Transpl. 2019;8:38\u201344.","journal-title":"Cell Ther Transpl"},{"key":"2068_CR27","doi-asserted-by":"publisher","first-page":"100508","DOI":"10.1016\/j.repbio.2021.100508","volume":"21","author":"P Pethe","year":"2021","unstructured":"Pethe P, Kale V. Placenta: A Gold Mine for Research and Regenerative Medicine. Reproductive Biol. 2021;21:100508.","journal-title":"Reproductive Biol"},{"key":"2068_CR28","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1080\/10428194.2021.1872072","volume":"62","author":"A Prabahran","year":"2021","unstructured":"Prabahran A, Koldej R, Chee L, Wong E, Ritchie D. Evaluation of Risk Factors for and Subsequent Mortality from Poor Graft Function (PGF) Post Allogeneic Stem Cell Transplantation. Leukemia Lymphoma. 2021;62:1482\u20139.","journal-title":"Leukemia Lymphoma"},{"key":"2068_CR29","doi-asserted-by":"publisher","first-page":"e13225","DOI":"10.1111\/tid.13225","volume":"22","author":"J Signorelli","year":"2020","unstructured":"Signorelli J, Zimmer A, Liewer S, Shostrom VK, Freifeld A. Incidence of Febrile Neutropenia in Autologous Hematopoietic Stem Cell Transplant (HSCT) Recipients on Levofloxacin Prophylaxis. Transplant Infectious Dis. 2020;22:e13225.","journal-title":"Transplant Infectious Dis"},{"key":"2068_CR30","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00277-020-04132-0","volume":"99","author":"L Rearigh","year":"2020","unstructured":"Rearigh L, Stohs E, Freifeld A, Zimmer A. De-escalation of Empiric Broad Spectrum Antibiotics in Hematopoietic Stemm Cell transplant Recipients with Febrile Neutropenia. Ann Hematol. 2020;99:1917\u201324.","journal-title":"Ann Hematol"},{"key":"2068_CR31","unstructured":"Online Document: Auletta JJ, Kou J, Chen M, Shaw BE. Current Use and Outcome of Hematopoietic Stem Cell Transplantation: CIBMTR US Summary Slides, 2021. https:\/\/www.cibmtr.org\/ReferenceCenter\/SlidesReports\/SummarySlides\/pages\/index.aspx. Accessed 30 Oct 2022."}],"updated-by":[{"DOI":"10.1038\/s41409-024-02469-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000}}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02068-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02068-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02068-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T07:03:33Z","timestamp":1733295813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02068-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2068"],"URL":"https:\/\/doi.org\/10.1038\/s41409-023-02068-3","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41409-024-02469-y","asserted-by":"object"}]},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,8]]},"assertion":[{"value":"17 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: Following the publication of this article, the authors noted the omission of \u2018et al\u2019 in reference 16. The authors would also like to add an additional reference as below to add context on the original discovery of PLX-R18\u2019s proposed therapeutic capabilities.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41409-024-02469-y","URL":"https:\/\/doi.org\/10.1038\/s41409-024-02469-y","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JPM has declared the following competing interests: Kite, Novartis, Bristol Myers Squibb, Allovir, Nektar, Sana, CRISPR (Ad Boards and consulting). LM has declared the following competing interests: Incyte (promotional speaker). LP has no competing interests. ML has declared the following competing interests: clinical trial finding (Abbvie, Amgen, Astellas, Novartis, Syndax, Actinium, Pluri-Biotech); advisory board (Jazz Pharmaceuticals); data monitoring board (BioSight). SDR has declared the following competing interests: SIRPant Immunotherapeutics (community advisory board), Realta Life Sciences (consultant). BA has no competing financial interests. RT has no competing financial interests. HML has declared the following competing interests: Actinium pharmaceuticals, Inc (consultant); Partner Therapeutics (consultant and stock options); Jazz Pharmaceuticals (speaker bureau and consultant); Pluri-Biotech, Inc.(consultant); Bristol-Myers Squibb (data safety monitoring board); Seattle Genetics (consultant and promotional speaker); AstraZeneca (promotional speaker); BioSight (data safety monitoring board); CSL Behring (consultant). JMR has declared the following competing interests: BioSight (consultant); Pluri-Biotech, Inc. (consultant). TZ has received honoraria from AbbVie, Orgenesis Inc, BioSight Ltd, Cellect Biotechnology, Janssen, Novartis and Gilead Sciences for participating in an advisory board or speaker\u2019s bureau. MS, DR and NH are current employees of Pluri-Biotech.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}